ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2085

Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis

Antonia Valenzuela1, Lorinda Chung2, Livia Casciola-Rosen3, Antony Rosen3 and David Fiorentino4, 1Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 2Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 3Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 4Dermatology, Stanford University School of Medicine, Redwood City, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, calcinosis and dermatomyositis

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Prior studies have estimated that 20% of adult dermatomyositis (DM) patients suffer from calcinosis.  Although calcinosis is related to persistent disease activity, poor treatment adherence, and therapy refractoriness in juvenile DM (JDM) patients, risk factors for calcinosis in the adult DM population have not been extensively studied.  Antibodies to nuclear matrix protein 2 (NXP-2) have been associated with calcinosis in JDM patients but only one study has shown a trend for this association in adult DM.  We aimed to determine the prevalence of calcinosis and to identify associated clinical features in a large cohort of adult DM patients. 

Methods: This is a cross-sectional study of 126 patients diagnosed with DM at Stanford University Medical Center between 01/2006 and 01/2013. Calcinosis was defined as the presence of calcium deposition in the skin and/or subcutaneous tissues as determined by physical examination and/or radiography. Logistic regression was used to obtain odds ratios (OR) relating calcinosis to various clinical features using both univariate and multivariate analyses. 

Results: 94% of patients had DM-specific or myositis-specific autoantibodies (against NXP-2, transcription intermediary factor-gamma (TIF-g), melanoma differentiation antigen 5 (MDA-5), sumoyl activating enzyme (SAE1/2), Mi-2, or Jo-1). A total of 14 (11%) patients had calcinosis. In univariate analysis, longer disease duration (OR=1.1, 95%CI 1.01–1.3, p=0.03), digital ulcers (OR=9.8, 95%CI 2.9–33.6, p=0.0003), interstitial lung disease (OR=6.5, 95%CI 1.9–22.2, p=0.003), autoantibodies to MDA-5 (OR=5.1, 95%CI 1.4–17.8, p=0.01) and antibodies to Ro52 (OR=3.5, 95%CI 1.1-11.0, p=0.04) were positively associated with calcinosis while autoantibodies to TIF-g were negatively associated with calcinosis (OR=0.19, 95%CI 0.04–0.91, p=0.04). The association between anti-NXP-2 and calcinosis reached statistical significance only in multivariate analysis (OR=7.6, 95%CI 1.5–39.2, p=0.01), while MDA-5 and TIF-g were no longer significantly associated in these models. Because of the known association between MDA-5 and digital ulcers, we evaluated a multivariate model excluding digital ulcers, and found that MDA-5 positivity was highly predictive of calcinosis (OR=6.9, 95%CI 1.8–27, p=0.005).  Digital ulcers were strongly associated with calcinosis in all multivariate models, independent of the underlying autoantibody present (Table 1). 

Conclusion: Calcinosis was a relatively uncommon clinical feature in our cohort of DM patients. We found an association between calcinosis and anti-NXP-2 autoantibodies as well as a novel association with digital ulcers. A common vascular mechanism may underlie the development of both calcinosis and digital ulcers in patients with DM.

Table 1. Predictors of calcinosis in multivariate analyses.

 

OR

95%CI

p-value

Multivariate model 1

Disease duration

1.2

1.04 – 1.38

0.01

Digital ulcers

23.1

4.74 – 112

<0.001

NXP-2

7.6

1.48 – 39.2

0.01

 

Multivariate model 2

Disease duration

1.17

1.04 – 1.33

0.01

Digital ulcers

12.8

2.12 – 77.2

0.005

MDA-5

1.19

0.17 – 8.04

0.85

 

Multivariate model 3

Disease duration

1.16

1.03 – 1.3

0.01

MDA-5

6.9

1.76 – 27

0.005

 

Multivariate model 4

Disease duration

1.16

1.03 – 1.33

0.01

Digital ulcers

13.9

3.31 – 58.6

0.0003

TIF-g

0.24

0.04 – 1.25

0.09


Disclosure:

A. Valenzuela,
None;

L. Chung,
None;

L. Casciola-Rosen,
None;

A. Rosen,

Sanofi-Aventis Pharmaceutical,

5,

Inova Diagnostics, Inc.,

7;

D. Fiorentino,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-clinical-features-and-risk-factors-associated-with-calcinosis-in-adult-patients-with-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology